Abstract

Genomic instability is a fundamental feature of human cancer often resulting from impaired genome maintenance. In prostate cancer, structural genomic rearrangements are a common mechanism driving tumorigenesis. However, somatic alterations predisposing to chromosomal rearrangements in prostate cancer remain largely undefined. Here, we show that SPOP, the most commonly mutated gene in primary prostate cancer, modulates DNA double strand break (DSB) repair, and that SPOP mutation is associated with genomic instability. In vivo, SPOP mutation results in a transcriptional response consistent with BRCA1 inactivation resulting in impaired homology-directed repair (HDR) of DSB. Furthermore, we found that SPOP mutation sensitizes to DNA damaging therapeutic agents such as PARP inhibitors. These results implicate SPOP as a novel participant in DSB repair, suggest that SPOP mutation drives prostate tumorigenesis in part through genomic instability, and indicate that mutant SPOP may increase response to DNA damaging therapeutics.

Article and author information

Author details

  1. Gunther Boysen

    Department of Pathologygy and Laboratory Medicine, Weill Cornell Medical College, New York, United Kingdom
    Competing interests
    No competing interests declared.
  2. Christopher E Barbieri

    Department of Urologygy, Weill Cornell Medical College, New York, United States
    Competing interests
    Christopher E Barbieri, A patent (US Patent Application No: 2013/0331,279) has been issued to Weill Medical College of Cornell University on SPOP mutations in prostate cancer; is listed as co-inventor.
  3. Davide Prandi

    Centre for Integrative Biologygy, University of Trento, Trento, Italy
    Competing interests
    No competing interests declared.
  4. Mirjam Blattner

    Department of Pathologygy and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    Competing interests
    No competing interests declared.
  5. Sung-Suk Chae

    Department of Pathologygy and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    Competing interests
    No competing interests declared.
  6. Arun Dahija

    Department of Pathologygy and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    Competing interests
    No competing interests declared.
  7. Srilakshmi Nataraj

    Department of Pathologygy and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    Competing interests
    No competing interests declared.
  8. Dennis Huang

    Department of Pathologygy and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    Competing interests
    No competing interests declared.
  9. Clarisse Marotz

    Department of Pathologygy and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    Competing interests
    No competing interests declared.
  10. Limei Xu

    Department of Pathologygy and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    Competing interests
    No competing interests declared.
  11. Julie Huang

    Department of Pathologygy and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    Competing interests
    No competing interests declared.
  12. Paola Lecca

    Centre for Integrative Biologygy, University of Trento, Trento, Italy
    Competing interests
    No competing interests declared.
  13. Sagar Chhangawala

    Department of Surgery, Weill Cornell Medical College, New York, United States
    Competing interests
    No competing interests declared.
  14. Deli Liu

    Department of Urologygy, Weill Cornell Medical College, New York, United States
    Competing interests
    No competing interests declared.
  15. Pengbo Zhou

    Department of Pathologygy and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    Competing interests
    No competing interests declared.
  16. Andrea Sboner

    Department of Pathologygy and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    Competing interests
    No competing interests declared.
  17. Johann S de Bono

    Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom
    Competing interests
    No competing interests declared.
  18. Francesca Demichelis

    Centre for Integrative Biologygy, University of Trento, Trento, Italy
    Competing interests
    No competing interests declared.
  19. Yariv Houvras

    Department of Surgery, Weill Cornell Medical College, New York, United States
    Competing interests
    No competing interests declared.
  20. Mark A Rubin

    Department of Pathologygy and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    For correspondence
    rubinma@med.cornell.edu
    Competing interests
    Mark A Rubin, A patent (US Patent Application No: 2013/0331,279) has been issued to Weill Medical College of Cornell University on SPOP mutations in prostate cancer; is listed as co-inventor.

Ethics

Animal experimentation: All protocols were performed with prior approval of the WCMC IACUC under protocol 2012-0065.

Copyright

© 2015, Boysen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 7,219
    views
  • 1,474
    downloads
  • 144
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gunther Boysen
  2. Christopher E Barbieri
  3. Davide Prandi
  4. Mirjam Blattner
  5. Sung-Suk Chae
  6. Arun Dahija
  7. Srilakshmi Nataraj
  8. Dennis Huang
  9. Clarisse Marotz
  10. Limei Xu
  11. Julie Huang
  12. Paola Lecca
  13. Sagar Chhangawala
  14. Deli Liu
  15. Pengbo Zhou
  16. Andrea Sboner
  17. Johann S de Bono
  18. Francesca Demichelis
  19. Yariv Houvras
  20. Mark A Rubin
(2015)
SPOP mutation leads to genomic instability in prostate cancer
eLife 4:e09207.
https://doi.org/10.7554/eLife.09207

Share this article

https://doi.org/10.7554/eLife.09207

Further reading

    1. Cancer Biology
    2. Cell Biology
    Maojin Tian, Le Yang ... Peiqing Zhao
    Research Article

    TIPE (TNFAIP8) has been identified as an oncogene and participates in tumor biology. However, how its role in the metabolism of tumor cells during melanoma development remains unclear. Here, we demonstrated that TIPE promoted glycolysis by interacting with pyruvate kinase M2 (PKM2) in melanoma. We found that TIPE-induced PKM2 dimerization, thereby facilitating its translocation from the cytoplasm to the nucleus. TIPE-mediated PKM2 dimerization consequently promoted HIF-1α activation and glycolysis, which contributed to melanoma progression and increased its stemness features. Notably, TIPE specifically phosphorylated PKM2 at Ser 37 in an extracellular signal-regulated kinase (ERK)-dependent manner. Consistently, the expression of TIPE was positively correlated with the levels of PKM2 Ser37 phosphorylation and cancer stem cell (CSC) markers in melanoma tissues from clinical samples and tumor bearing mice. In summary, our findings indicate that the TIPE/PKM2/HIF-1α signaling pathway plays a pivotal role in promoting CSC properties by facilitating the glycolysis, which would provide a promising therapeutic target for melanoma intervention.

    1. Cell Biology
    Zewei Zhao, Longyun Hu ... Zhonghan Yang
    Research Article

    The induction of adipose thermogenesis plays a critical role in maintaining body temperature and improving metabolic homeostasis to combat obesity. β3-adrenoceptor (β3-AR) is widely recognized as a canonical β-adrenergic G-protein-coupled receptor (GPCR) that plays a crucial role in mediating adipose thermogenesis in mice. Nonetheless, the limited expression of β3-AR in human adipocytes restricts its clinical application. The objective of this study was to identify a GPCR that is highly expressed in human adipocytes and to explore its potential involvement in adipose thermogenesis. Our research findings have demonstrated that the adhesion G-protein-coupled receptor A3 (ADGRA3), an orphan GPCR, plays a significant role in adipose thermogenesis through its constitutively active effects. ADGRA3 exhibited high expression levels in human adipocytes and mouse brown fat. Furthermore, the knockdown of Adgra3 resulted in an exacerbated obese phenotype and a reduction in the expression of thermogenic markers in mice. Conversely, Adgra3 overexpression activated the adipose thermogenic program and improved metabolic homeostasis in mice without exogenous ligand. We found that ADGRA3 facilitates the biogenesis of beige human or mouse adipocytes in vitro. Moreover, hesperetin was identified as a potential agonist of ADGRA3, capable of inducing adipocyte browning and ameliorating insulin resistance in mice. In conclusion, our study demonstrated that the overexpression of constitutively active ADGRA3 or the activation of ADGRA3 by hesperetin can induce adipocyte browning by Gs-PKA-CREB axis. These findings indicate that the utilization of hesperetin and the selective overexpression of ADGRA3 in adipose tissue could serve as promising therapeutic strategies in the fight against obesity.